Salman Hussain is a panelist during the conference. He is discussing patient-focused drug development, bringing a precision medicine approach to alopecia areata, and the latest patient reported outcomes tools and biomarker studies. The roundtable discussion includes representatives from several pharmaceutical companies, a couple physicians/researchers, and patient advocacy group members.
For more inforamtion on this event, click here.
CRA's RADAR Insights: Impact of US pricing strategies on orphan drug pricing in Germany - Part 3
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...